Get an understanding by watching videos on the pathogenesis and natural course of NAFLD and NASH.
Discover the intricate dynamics of Clinical Chemistry in NAFLD with Dr. Guillaume Grzych, a leading expert in medical biology and advanced computational techniques. Dive deep into the pathophysiology of liver fibrosis, explore the potential of biomarkers, and understand diagnostic tools like the AST-to-ALT ratio, FibroTest, APRI, FIB-4, and the ELF Score.
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients - a deep-dive into two groundbreaking studies from the US and France. Explore the findings and their implications for future diabetes care.
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his own case study.
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This video is adapted from a lecture Dr. Scott Friedman gave at the Paris NASH meeting and illustrates the highlights of that topic in this video.
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed in this video are that co-existent fatty liver and related metabolic factors, including obesity and diabetes mellitus, exacerbate liver injury in patients with another chronic liver disease(s).
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.
Dr. Nicolas Lanthier (Belgium) reviews the interaction between the gut microbiota and PPARs in NAFLD. He discusses the microbiota and its link to NAFLD and IR, where he explains the key role of the gut microbes in the metabolism of their host and highlights how liver becomes the first organ to be exposed to gut changes.
Dr. Moritz Peiseler (La Charité - Germany), discusses new scientific insights into the role of inflammation in NAFLD / NASH. He presents the spectrum of NAFLD and explains how inflammation can drive all the progressive stages of NAFLD. He also reviews hepatocellular carcinoma (HCC) risks and presents several studies and evolving treatments for NASH.
Prof. Pierre-E.Rautou (France) discusses the effects of Liver Sinusoidal endothelial cell (LSEC) capillarization in patients with NASH. He also reviews the occurrences of LSEC capillarization at the early stages of NASH and its contribution to NASH progression by favoring inflammation and liver fibrosis. For the clinicians, he demonstrates a 24 week study of patients with NASH, exposed placebo and lanifibranor treatments strategies to determine LSEC changes.